Early experience with 70-150 m irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases

Anticancer Research

Volumn 36, Issue 7, 2016, Pages 3413-3418

  Akinwande, Olaguoke ^a   Scoggins, Charles ^b   Martin, Robert C G ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Chemoembolization; Colorectal; DEBIRI; Irinotecan; Metastases

Indexed keywords

BILIRUBIN; CARCINOEMBRYONIC ANTIGEN; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DELAYED RELEASE FORMULATION; MICROSPHERE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER CONTROL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; DRUG DELIVERY DEVICE; DRUG ELUTING BEAD; DRUG SAFETY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT RESPONSE; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DELAYED RELEASE FORMULATION; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DELAYED-ACTION PREPARATIONS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84992166488     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Poggi G, Quaretti P, Minoia C, Bernardo G, Bonora MR, Gaggeri R, Ronchi A, Saluzzo CM, Azzaretti A, Rodolico G, Montagna M, Amatu A, Teragni C, Palumbo I, Traverso E, Tonini S, Villani L, Scelsi M, Baiardi P, Felisi MG, Sottotetti F, Tagliaferri B and Riccardi A: Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 28(6B): 3835-3842, 2008.
2. Albert M, Kiefer MV, Sun W, Haller D, Fraker DL, Tuite CM, Stavropoulos SW, Mondschein JI and Soulen MC: Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 117(2): 343-352, 2011.
3. Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA, Jr., Barakat O, Benson A, 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA and Salem R: Unresectable chemorefractory liver metastases: Radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology 247(2): 507-515, 2008.
4. Goere D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, Dromain C, Ducreux M and Elias D: Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 251(4): 686-691, 2010.
5. van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM, Rossleigh MA, Taylor DJ and George J: Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27(25): 4089-4095, 2009.
6. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, 2nd, Zhang C and Mayer RJ: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24(9): 1395-1403, 2006.
7. van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland AH, Ferguson T, Rodriguez J, Kroning H, Wolf I, Ganju V, Walpole E, Boucher E, Tichler T, Shacham-Shmueli E, Powell A, Eliadis P, Isaacs R, Price D, Moeslein F, Taieb J, Bower G, Gebski V, Van Buskirk M, Cade DN, Thurston K and Gibbs P: Sirflox: Randomized phase iii trial comparing first-line MFOLFOX6 (plus or minus bevacizumab) versus MFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 34(15): 1723-1731, 2016.
8. Martin RC, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M, Padr R, Rocek M, Scupchenko A and Tatum C: Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: Results of multi-institutional study. Ann Surg Oncol 18(1): 192-198, 2011.
9. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V and Coschiera P: Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (folfiri) for hepatic metastases from colorectal cancer: Final results of a phase III study. Anticancer Res 32(4): 1387-1395, 2012.
10. Iezzi R, Marsico VA, Guerra A, Cerchiaro E, Cassano A, Basso M, Devicienti E, Rodolfino E, Barone C and Bonomo L: Transarterial chemoembolization with irinotecan-loaded drug-eluting beads (debiri) and capecitabine in refractory liver prevalent colorectal metastases: A phase ii single-center study. Cardiovasc Intervent Radiol 38(6): 1523-1531, 2015.
11. Akinwande O, Miller A, Hayes D, O'Hara R, Tomalty D and Martin RC: Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. Anticancer Res 34(12): 7239-7245, 2014.
12. Narayanan G, Barbery K, Suthar R, Guerrero G and Arora G: Transarterial chemoembolization using debiri for treatment of hepatic metastases from colorectal cancer. Anticancer Res 33(5): 2077-2083, 2013.
13. Martin RC, 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS and Strasberg SM: Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 121(20): 3649-3658, 2015.
14. Dreher MR, Sharma KV, Woods DL, Reddy G, Tang Y, Pritchard WF, Chiesa OA, Karanian JW, Esparza JA, Donahue D, Levy EB, Willis SL, Lewis AL and Wood BJ: Radiopaque drugeluting beads for transcatheter embolotherapy: Experimental study of drug penetration and coverage in swine. J Vasc Interv Radiol 23(2): 257-264 e254, 2012.
15. Lee KH, Liapi E, Vossen JA, Buijs M, Ventura VP, Georgiades C, Hong K, Kamel I, Torbenson MS and Geschwind JF: Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: Evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol 19(10): 1490-1496, 2008.
16. Akinwande OK, Philips P, Duras P, Pluntke S, Scoggins C and Martin RC: Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: A propensity score matching analysis. Cardiovasc Intervent Radiol 38(2): 361-371, 2015.
17. Padia SA, Shivaram G, Bastawrous S, Bhargava P, Vo NJ, Vaidya S, Valji K, Harris WP, Hippe DS and Kogut MJ: Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: Comparison of small-versus mediumsize particles. J Vasc Interv Radiol 24(3): 301-306, 2013.
18. Martin R, Irurzun J, Munchart J, Trofimov I, Scupchenko A, Tatum C and Narayanan G: Optimal technique and response of doxorubicin beads in hepatocellular cancer: Bead size and dose. Korean J Hepatol 17(1): 51-60, 2011.
19. Spreafico C, Cascella T, Facciorusso A, Sposito C, Rodolfo L, Morosi C, Civelli EM, Vaiani M, Bhoori S, Pellegrinelli A, Marchiano A and Mazzaferro V: Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: Clinical-radiological outcomes and safety profile. Cardiovasc Intervent Radiol 38(1): 129-134, 2015.
20. Odisio BC, Ashton A, Yan Y, Wei W, Kaseb A, Wallace MJ, Vauthey JN, Gupta S and Tam AL: Transarterial hepatic chemoembolization with 70-150 micron drug-eluting beads: Assessment of clinical safety and liver toxicity profile. J Vasc Interv Radiol 26(7): 965-971, 2015.
21. Martin RC, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic PM and Tatum C: Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: Results of a multi-institutional registry. Cardiovascular and interventional radiology 33(5): 960-966, 2010.
22. Martin RC, Joshi J, Robbins K, Tomalty D, O'Hara R and Tatum C: Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): Multiinstitutional registry. J Oncol 2009: 539795, 2009.
23. Lewandowski RJ, Wang D, Gehl J, Atassi B, Ryu RK, Sato K, Nemcek AA Jr., Miller FH, Mulcahy MF, Kulik L, Larson AC, Salem R and Omary RA: A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/mr imaging monitoring. J Vasc Interv Radiol 18(10): 1249-1257, 2007.
24. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: Ctcae v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3): 176-181, 2003.
25. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and Benjamin RS: Correlation of computed tomography and positron-emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25(13): 1753-1759, 2007.
26. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J and Gores GJ: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10): 698-711, 2008.
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). EurJ Cancer 45(2): 228-247, 2009.
28. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS and Fan ST: A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5(9): 1100-1108, 2007.
29. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montana X, Llovet JM and Bruix J: Chemoembolization of hepatocellular carcinoma with drugeluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3): 474-481, 2007.
30. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, Delis S, Gouliamos A and Kelekis D: Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug-eluting beads: Results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31(2): 269-280, 2008.
31. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R and Investigators PV: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the precision V study. Cardiovasc Intervent Radiol 33(1): 41-52, 2010.
32. Lewis AL, Dreher MR, O'Byrne V, Grey D, Caine M, Dunn A, Tang Y, Hall B, Fowers KD, Johnson CG, Sharma KV and Wood BJ: DC BeadM1: Towards an optimal transcatheter hepatic tumour therapy. J Mater Sci Mater Med 27(1): 13, 2016.